The DOI matches its Crossref record; 284 of the 286 references it cites were found in a registry or an index.
Progress in brain targeting drug delivery system by nasal route
Abstract
The blood-brain barrier (BBB) restricts the transport of potential therapeutic moieties to the brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the BBB has gained an important consideration for delivery of wide range of therapeutics to brain. Intranasal route of transportation directly delivers the drugs to brain without systemic absorption, thus avoiding the side effects and enhancing the efficacy of neurotherapeutics. Over the last several decades, different drug delivery systems (DDSs) have been studied for targeting the brain by the nasal route. Novel DDSs such as nanoparticles (NPs), liposomes and polymeric micelles have gained potential as useful tools for targeting the brain without toxicity in nasal mucosa and central nervous system (CNS). Complex geometry of the nasal cavity presented a big challenge to effective delivery of drugs beyond the nasal valve. Recently, pharmaceutical firms utilized latest and emerging nasal drug delivery technologies to overcome these barriers. This review aims to describe the latest development of brain targeted DDSs via nasal administration.Chemical compounds studied in this article Carbopol 934p (PubChem CID: 6581) Carboxy methylcellulose (PubChem CID: 24748) Penetratin (PubChem CID: 101111470) Poly lactic-co-glycolic acid (PubChem CID: 23111554) Tween 80 (PubChem CID: 5284448).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most investigated administration route for micelles is the intravenous (i.v.) injection/infusion (mainly exploited for chemotherapy) [18,[47][48][49], but very interesting results in terms of improved drug bioavailability have also been reported following oral [31,50] and topical (ocular, nasal, buccal) [26,36,51,52] administration.”
From Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions (2021) · cites this paper as [50]
Citations
Cites
1 retracted
Pal, A., Gupta, S., Jaiswal, A. K., Dube, A., & Vyas, S. P. (2011) · Journal of Liposome Research · doi:10.3109/08982104.2011.592495 · Cited by 39
RetractedRecent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 2×
“Most of the research over last several years was focused on polymeric NPs based on poly (lactic acid) (PLA), poly (D.L-lactide-co-glycolide) (PLGA) and poly (glycolic acid) (PGA) for brain targeted delivery [85].”
BackgroundDaneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Rejman, J., Oberle, V., Zuhorn, I. S., & Hoekstra, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,872
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,256
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Nasal drug delivery—possibilities, problems and solutions
Illum, L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00363-2 · Cited by 1,139
Flagged first, then by citations
2 of the 286 references couldn’t be matched to a known paper.
Research works printed but not linked: 10
- Prados, 2003, A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma, Neuro-Oncology, 5, 96, 10.1093/neuonc/5.2.96 · DOI
- Sanjay, 2011, Der Pharmac. Sin., 2, 94
- Huang, 1996, Microsphere transport pathways in the rabbit nasal mucosa, Int. J. Pharm. Adv., 1, 298
- Aswathy, 2013, Emulsomes: a novel liposoomal formulation for sustained drug delivery, Int. Res. J. Pharm., 3, 192
- Desai, 2012, Evaluation of brain targeting for the nasal delivery of midazolam, Int. J. Pharm. Sci. Rev. Res., 12, 109
- Kanazawa, 2011, Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration, Pharm. Res., 28, 2130, 10.1007/s11095-011-0440-7 · DOI · Paper page
- Patel, 2012, Nanocarriers as novel nose-to-brain targeted drug delivery platforms, Indian J. Nov. Drug Deliv, 4, 243
- Abdelbary, 2013, Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in-vitro characterization, ex-vivo estimation of nasal toxicity and in-vivo biodistribution studies, Int. J. Pharm., 452
- Haruta, 2012, Meeting the needs for nasal delivery devices for powder formulations, Drug Dev. Deliv., 12, 22
- Suman, 1999, Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump, Pharm. Res., 16, 1648, 10.1023/A:1011933410898 · DOI
Cited by
Sorted by citations
Items 401–403 of 403
Min, J., Gao, J., Hao, Z., Wu, X., Liptrott, N. J., Yang, J., 陈怡钊, & Ruan, G. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00124
Metadata
- Authors
- Khan, A. R., Liu, M., Khan, M. W., & Zhai, G.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Zhai, Guangxi
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 268
- Pages
- 364-389
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2750980441
- Cited by
- 402
- References
- 286
- Citations by year
- 2026: 23 · 2025: 54 · 2024: 61 · 2023: 50 · 2022: 60 · 2021: 56 · 2020: 41 · 2019: 36 · 2018: 20 · 2017: 1
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- China-Australia Centre for Health Sciences Research (2016GJ01)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- intranasal drug delivery, blood-brain barrier, olfactory pathway, trigeminal pathway, nanoparticles, liposomes, polymeric micelles, nasal mucosa, neurotherapeutics, Carbopol 934P, carboxymethyl cellulose, penetratin, PLGA, Tween 80
- MeSH terms
- Administration, Intranasal, Animals, Brain, Humans, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
